IMC
$10M23mo
Immuron
Gastrointestinal
Hyperimmune bovine colostrum antibodies for traveller's diarrhoea and NASH (Travelan, IMM-124E)
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$10.0M
Dec 2025 4C
Runway
23moSTABLE
Based on Dec 2025 4C
Market Cap
$10M
Burn Rate
$1.3M/qtr
Dec 2025 4C
Shares Outstanding
327M
Pipeline Assets
3
Latest Insight(1)
26 Feb 2026substantial_holderChange in substantial holding
Changed·The Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A·41.25%
3M Price
IMC.ASX$0.032-13.5% 3M
Low $0.026High $0.039
Pipeline Assets (3)
IMM-124Etravellers diarrhoea prevention
Phase 2IMM-529clostridioides difficile infection
Phase 2Travelantravellers diarrhoea prevention
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Substantial Holders (5%+ threshold)
2 noticesarrow_drop_downThe Bank of New York Mellon Corporation and each Group Entity listed in Annexure A
41.25%2026-02-26
arrow_drop_downThe Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A
41.25%2026-02-26
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
3 approved drugs16 competitor trialsPhase 2+ · Non-ASX
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (6)· 0 upcoming · 6 past
expand_more6 past catalysts
Confirmedarrow_upwardHigh8 Apr 2026
Results available at https://clinicaltrials.gov/study/NCT01968382
Confirmedarrow_upwardHigh8 Apr 2026
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
★ RESULTS
Clinical Trials(1)
No active trials